Pablo Hofbauer1, Sabrina Riedl1, Karin Witzeneder2, Florian Hildner3, Susanne Wolbank1, Marion Groeger4, Christian Gabriel2, Heinz Redl1, Wolfgang Holnthoner5. 1. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Austrian Cluster for Tissue Regeneration, Vienna, Austria. 2. Red Cross Blood Transfusion Service of Upper Austria, Austrian Cluster for Tissue Regeneration, Linz, Austria. 3. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Austrian Cluster for Tissue Regeneration, Vienna, Austria; Red Cross Blood Transfusion Service of Upper Austria, Austrian Cluster for Tissue Regeneration, Linz, Austria. 4. Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria. 5. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Austrian Cluster for Tissue Regeneration, Vienna, Austria; Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria. Electronic address: wolfgang.holnthoner@trauma.lbg.ac.at.
Abstract
BACKGROUND AIMS: As angiogenic and lymphangiogenic key players, endothelial cells (ECs) are promising candidates for vascular regenerative therapies. To culture ECs in vitro, fetal calf serum (FCS) is most often used. However, some critical aspects of FCS usage, such as possible internalization of xenogeneic proteins and prions, must be considered. Therefore, the aim of this project was to determine if human platelet lysate (hPL) is a suitable alternative to FCS as medium supplement for the culture of blood vascular and lymphatic endothelial cells. METHODS: The usability of hPL was tested by analysis of endothelial surface marker expression, metabolic activity and vasculogenic potential of outgrowth ECs (OECs), human umbilical vein ECs (HUVECs), and lymphatic ECs (LECs). RESULTS: Expression of EC markers CD31, VEGFR2, VE-cadherin and CD146 did not differ significantly between the EC types cultured in FCS or hPL. In addition, OECs, HUVECs and LECs formed tube-like structures on Matrigel when cultured in hPL and FCS. With the use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid assays, we found that the metabolic activity of OECs and LECs was slightly decreased when hPL was used. However, HUVECs and LECs did not show a significant decrease in metabolic activity, and HUVECs showed a slightly higher activity at low seeding densities. CONCLUSIONS: The use of hPL on different EC types did not reveal any substantial negative effects on EC behavior. Thus, hPL appears to be a favorable candidate to replace FCS as a medium supplement in the culture of ECs.
BACKGROUND AIMS: As angiogenic and lymphangiogenic key players, endothelial cells (ECs) are promising candidates for vascular regenerative therapies. To culture ECs in vitro, fetal calf serum (FCS) is most often used. However, some critical aspects of FCS usage, such as possible internalization of xenogeneic proteins and prions, must be considered. Therefore, the aim of this project was to determine if human platelet lysate (hPL) is a suitable alternative to FCS as medium supplement for the culture of blood vascular and lymphatic endothelial cells. METHODS: The usability of hPL was tested by analysis of endothelial surface marker expression, metabolic activity and vasculogenic potential of outgrowth ECs (OECs), human umbilical vein ECs (HUVECs), and lymphatic ECs (LECs). RESULTS: Expression of EC markers CD31, VEGFR2, VE-cadherin and CD146 did not differ significantly between the EC types cultured in FCS or hPL. In addition, OECs, HUVECs and LECs formed tube-like structures on Matrigel when cultured in hPL and FCS. With the use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid assays, we found that the metabolic activity of OECs and LECs was slightly decreased when hPL was used. However, HUVECs and LECs did not show a significant decrease in metabolic activity, and HUVECs showed a slightly higher activity at low seeding densities. CONCLUSIONS: The use of hPL on different EC types did not reveal any substantial negative effects on EC behavior. Thus, hPL appears to be a favorable candidate to replace FCS as a medium supplement in the culture of ECs.
Authors: R Fazzina; P Iudicone; A Mariotti; D Fioravanti; A Procoli; E Cicchetti; G Scambia; G Bonanno; L Pierelli Journal: Cytotechnology Date: 2015-05-06 Impact factor: 2.058
Authors: Dimitar Tasev; Michiel H van Wijhe; Ester M Weijers; Victor W M van Hinsbergh; Pieter Koolwijk Journal: PLoS One Date: 2015-06-15 Impact factor: 3.240
Authors: Sabrina Rohringer; Wolfgang Holnthoner; Matthias Hackl; Anna M Weihs; Dominik Rünzler; Susanna Skalicky; Michael Karbiener; Marcel Scheideler; Johannes Pröll; Christian Gabriel; Bernhard Schweighofer; Marion Gröger; Andreas Spittler; Johannes Grillari; Heinz Redl Journal: PLoS One Date: 2014-12-11 Impact factor: 3.240
Authors: Aranzazu Villasante; Samuel T Robinson; Andrew R Cohen; Roberta Lock; X Edward Guo; Gordana Vunjak-Novakovic Journal: Front Bioeng Biotechnol Date: 2021-07-13
Authors: Virginie Philippe; Alexis Laurent; Philippe Abdel-Sayed; Nathalie Hirt-Burri; Lee Ann Applegate; Robin Martin Journal: Cartilage Date: 2021-07-30 Impact factor: 4.634